Sign In
Buy NVS
$153.38
+4.45 (+2.99%)
At Close: Jun 23, 2026
FDA approves Novartis Kisqali® to reduce risk of recurrence in people with HR+/HER2- early breast cancer
12:55pm, Tuesday, 17'th Sep 2024
Ad hoc announcement pursuant to Art. 53 LR Broad indication in HR+/HER2- stage II and III early breast cancer (EBC) at high risk of recurrence approximately doubles population eligible for CDK4/6 inhi
Why Novartis (NVS) is a Top Momentum Stock for the Long-Term
10:55am, Tuesday, 17'th Sep 2024
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Novartis Breast Cancer Drug Found To Cut Disease Recurrence
10:27am, Monday, 16'th Sep 2024
American depositary receipts (ADRs) of Novartis (NVS) gained Monday as new research showed the company's breast cancer treatment, Kisqali, produced longer success than originally thought.
Basel, September 16, 2024 – In an updated analysis from the pivotal Phase III NATALEE trial, investigational Kisqali® (ribociclib) added to endocrine therapy (ET) shows a deepening benefit beyond t
Boost Your Portfolio's Health With These 4 Large-Cap Drug Stocks
11:50am, Thursday, 12'th Sep 2024
Here are four big drug/biotech stocks, LLY, RHHBY, NVS and PFE, which you should buy today for lucrative long-term returns.
This Novartis Analyst Is No Longer Bullish; Here Are Top Downgrades For Wednesday
12:13pm, Wednesday, 11'th Sep 2024
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.
Novartis to License VYGR's Capsid for Gene Therapy in Neurology
10:26am, Friday, 06'th Sep 2024
NVS has decided to license a novel capsid generated from Voyager's TRACER platform for use in a gene therapy program against an undisclosed rare neurologic disease target.
Goldman Sachs Shifts Stance On Novartis, Cites Lack Of Near-Term Catalysts
02:34pm, Thursday, 05'th Sep 2024
Goldman Sachs has downgraded Novartis AG NVS, citing “limited value driving innovation catalysts in the near term.”
NVS or LLY: Which Is the Better Value Stock Right Now?
12:45pm, Wednesday, 04'th Sep 2024
Investors looking for stocks in the Large Cap Pharmaceuticals sector might want to consider either Novartis (NVS) or Eli Lilly (LLY). But which of these two stocks presents investors with the better v
Novartis (NVS) Upgraded to Buy: Here's What You Should Know
01:01pm, Tuesday, 03'rd Sep 2024
Novartis (NVS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Novartis' Cholesterol Drug Meets Primary Goals in Late-Stage Study
10:51am, Thursday, 29'th Aug 2024
NVS' late-stage study meets its primary endpoints, demonstrating the superiority of Leqvio monotherapy over both placebo and ezetimibe in LDL-C reduction.
Basel, August 28, 2024 – Novartis announced today positive topline results from twice-yearly* Leqvio® (inclisiran) in the Phase III V-MONO study, which met its primary endpoints. Leqvio monotherapy
Galapagos Surges On An FDA Win For Its Rival To Gilead, Novartis; But There Are Some Caveats
10:21am, Monday, 26'th Aug 2024
Galapagos stock surged Monday after the Food and Drug Administration cleared the biotech company to begin testing its cancer drug in people.
Siemens Healthineers to buy Novartis unit for over $223 million, FT reports
08:14am, Saturday, 24'th Aug 2024
Siemens Healthineers will pay more than 200 million euros ($223.8 million) to acquire the diagnostic arm of Advanced Accelerator Applications, owned by Novartis , the Financial Times reported on Satur
Top 10 pharmaceutical companies in 2024: S&P Global's latest ratings and rankings
01:57pm, Monday, 19'th Aug 2024
In the ever-evolving pharmaceutical landscape, financial stability and business resilience are crucial for long-term success. S&P Global, a leading financial information firm, recently released a comp
